- Scilex Holding Company (NASDAQ:SCLX) provided certain preliminary sales for ZTlido in Q1, 2024, and proposed plans to reduce research and development and other administrative expenses in 2024.
- The company estimates that ZTlido gross sales for Q1 2024 were in the range of $34M to $38M, compared to $27.5M for Q1 of 2023, representing growth in the range of about 24% to 38%.
- ZTlido net sales for Q1 2024 were in the range of $12M to $13M, compared to $10.6M for Q1 of 2023, representing growth in the range of approximately 13% to 23%.
- Scilex also plans to reduce R&D and other administrative expenses and to focus on its late-stage pipeline programs such as SP-102.
- Scilex has been working with its co-pay savings card adjudicators to resolve the recent breakdown of processing of insurance claims by Change Healthcare, following a cyber-attack on Change Healthcare.
- Scilex is aware of the impact this disruption has had on its patients and customers and has worked diligently to resolve the issue.
- As of today, co-pay savings card processing for ZTlido has been restored to normal operations.
- Source: Press Release
More on Scilex Holding Company